<DOC>
	<DOCNO>NCT02231021</DOCNO>
	<brief_summary>This study evaluate efficacy safety alogliptin pioglitazone combination therapy comparison either alogliptin pioglitazone glucose control metformin-treated type 2 diabetic patient Korea .</brief_summary>
	<brief_title>The Practical Evidence Antidiabetic Combination Therapy Korea</brief_title>
	<detailed_description>Pathophysiology type 2 diabetes know insulin resistance progressive beta cell dysfunction . Combination therapy biguanides , glucagon-like peptide-1 ( GLP-1 ) agonists dipeptidyl peptidase-4 inhibitor ( DPP4I ) thiazolidinediones ( TZD ) seem reasonable theoretically , effect different pathophysiologic defect . Current treatment guideline recommend stepwise approach start lifestyle modification lifestyle modification + metformin monotherapy , recent focus patient individualization . In Korea , Korean Diabetes Association also recommend stepwise approach time , emphasize initial aggressive treatment include oral combination insulin therapy accord HbA1c level achieve target goal &lt; 6.5 % . Guide efficacy , timing , option combination therapy clearly define due lack sufficient evidence yet . There clear report demonstrate clinical benefit initial TZD DPP4I combination therapy Korean . Thus reasonable study effect combination therapy patient sub-optimal glucose control metformin therapy , compare various combination option metformin DPP4I , TZD , . The hypothesis study combination therapy alogliptin pioglitazone add metformin superior effect HbA1c reduction metformin either alogliptin pioglitazone 6 month treatment .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Pioglitazone</mesh_term>
	<mesh_term>Alogliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>In opinion investigator , subject capable understanding comply protocol requirement The subject , applicable , subject 's legally acceptable representative sign date write , informed consent form require privacy authorization prior initiation study procedures The subject diagnose type 2 diabetes mellitus least 6 month Male female 19 75 year , inclusive 7.0 % = &lt; HbA1c = &lt; 10.0 % 18.5 Kg/m2 = &lt; Body Mass Index ( BMI ) = &lt; 45 kg/m2 systolic/diastolic blood pressure = &lt; 160/100 baseline hemoglobin least 12 g/dL men least 10 g/dL woman A female subject childbearing potential sexually active nonsterilized male partner agree routinely use adequate contraception singing inform consent throughout duration study Patient receive maximal tolerate dose metformin least 12 week without dose change ( metformin , &gt; = 1,000 mg/day fast cpeptide great 0.78 ng/mL ( 0.26 nmol/L ) baseline The patient receive investigational compound ( alogliptin pioglitazone ) within 180 day prior baseline Patient currently take need take andy medicine may exert significant influence blood glucose control except metformin . Severe renal disease : estimate glomerular filtration rate &lt; 50 mL/min Severe liver disease AST , ALT &gt; = 2.5 upper limit normal Cardiac status : New York Heart Association III ~ IV Hypopituitarism adrenal insufficiency Patient history major surgery , Severe infection , Severe trauma within 6 month Patients diagnose malignancy within 5yrs , Patients active bladder cancer Patient rare hereditary problem galactose intolerance , Lapp lactase deficiency glucosegalactose malabsorption Patient history hypersensitivity Alogliptin , Pioglitazone ingredients Pregnant lactate woman Patient history excessive alcohol abuse Subject involve clinical trial within 90 day prior initiation study . Subject investigator deems inappropriate participate study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Diabetes Mellitus , Type 2</keyword>
	<keyword>alogliptin</keyword>
	<keyword>pioglitazone</keyword>
	<keyword>DPP4 inhibitor</keyword>
	<keyword>thiazolidinedione</keyword>
</DOC>